Q-omics provides the consensus-scored PROKR2 profile across patient tissues and cancer cell-line models. PROKR2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PROKR2 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, PROKR2 protein abundance shows 21,787 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight SKCM, HNSC, and LUAD as cancer lineages where PROKR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROKR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROKR2 survival associations across molecular data types. PROKR2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROKR2 RNA expression–survival associations across cancer types. High PROKR2 expression shows unfavorable associations in COAD, KICH, HNSC, READ and PCPG, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PROKR2 RNA expression.
This table summarizes PROKR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PROKR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROKR2 shows lower tumor expression in HNSC, ESCA, THCA and KICH. The HNSC box plot shows higher PROKR2 RNA expression in normal versus tumor tissue (log2 FC = −0.142, t-test p = .023).
This table shows molecular features associated with PROKR2 in patient tissues and cancer cell lines. In patient samples, PROKR2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PROKR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
